Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19057815 | 0.85 | GLP1R (0.66) | GLP1RNOD1FOLH1 | |
| SCHEMBL23552462 | 0.85 | GLP1R (0.66) | GLP1RNOD1FOLH1 | |
| SCHEMBL22423516 | 0.85 | GLP1R (0.54) | GLP1RNOD1CASP2FAAH | |
| SCHEMBL19057814 | 0.85 | GLP1R (0.51) | GLP1RLPAR3NOD1CASP2FAAH | |
| SCHEMBL21572000 | 0.84 | GLP1R (0.48) | GLP1RFOLH1 | |
| SCHEMBL23544192 | 0.84 | GLP1R (0.53) | GLP1RNOD1CASP2FAAHSIRT2 | |
| SCHEMBL20936256 | 0.83 | GLP1R (0.55) | GLP1RLPAR3NOD1CASP2FAAH | |
| SCHEMBL21572002 | 0.82 | GLP1R (0.54) | GLP1RLPAR3NOD1CASP2FAAH | |
| SCHEMBL24092197 | 0.81 | GLP1R (0.55) | GLP1RNOD1CASP2FAAHFOLH1 | |
| SCHEMBL21572003 | 0.80 | GLP1R (0.70) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187074-A1 | TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187074-A1 | TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE | GCGR, GLP1R, GIPR | GLP1R 2/4885EPHX1 2064/4885LPAR3 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.